{"entity":{"id":"nektar-therapeutics","kind":"company","name":"Nektar Therapeutics","aka":["Nektar"],"tldr":"Nektar is a San Francisco biotechnology company whose polymer conjugation chemistry underlies several approved drugs and whose engineered interleukin-2, bempegaldesleukin, failed in phase 3 with nivolumab in 2022.","summary":"Nektar Therapeutics, listed on Nasdaq, built its business on PEGylation and polymer conjugate chemistry licensed into products such as pegfilgrastim-type molecules and movantik. Its own oncology bet, bempegaldesleukin (NKTR-214), a PEGylated interleukin-2 designed to favour effector T cells, was developed with Bristol Myers Squibb in a large phase 3 programme with nivolumab that reported negative results in melanoma, renal cell carcinoma and bladder cancer in 2022, after which the programme was closed. OnCo records it as a registry sponsor of phase 3 cancer trials.","asOf":"2026-09-11","wikipedia":"https://en.wikipedia.org/wiki/Nektar_Therapeutics","links":[{"label":"Official website","url":"https://www.nektar.com"},{"label":"ClinicalTrials.gov: trials led by Nektar Therapeutics","url":"https://clinicaltrials.gov/search?lead=Nektar%20Therapeutics"},{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/Nektar_Therapeutics"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["melanoma","rcc","urothelial"],"sections":["immunotherapy"],"technologies":[],"targets":[],"drugs":["bempegaldesleukin"],"companies":["bms"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"San Francisco, CA","country":"US","companyType":"biotech","website":"https://www.nektar.com","stage":"public","investors":[],"funding":[]},"route":"/companies/nektar-therapeutics/","neighbours":{"cancer":[{"id":"urothelial","kind":"cancer","name":"Bladder & urothelial cancer","route":"/cancers/urothelial/"},{"id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/"},{"id":"rcc","kind":"cancer","name":"Renal cell carcinoma","route":"/cancers/rcc/"}],"section":[{"id":"immunotherapy","kind":"section","name":"Immunotherapy","route":"/fronts/immunotherapy/"}],"drug":[{"id":"bempegaldesleukin","kind":"drug","name":"Bempegaldesleukin","route":"/drugs/bempegaldesleukin/"}],"company":[{"id":"bms","kind":"company","name":"Bristol Myers Squibb","route":"/companies/bms/"}],"trial":[{"id":"nct03729245","kind":"trial","name":"A Study of Bempegaldesleukin (NKTR-214: BEMPEG) in Combination With Nivolumab Compared With the Investigator's Choice of a Tyrosine Kinase Inhibitor (TKI) Therapy (Either Sunitinib or Cabozantinib Monotherapy) for Advanced Metastatic Renal Cell Carcinoma (RCC)","route":"/trials/nct03729245/"},{"id":"nct05632809","kind":"trial","name":"REStoring lymphoCytes Using NKTR-255* After chemoradiothErapy in Solid Tumors (RESCUE)","route":"/trials/nct05632809/"},{"id":"nct04410445","kind":"trial","name":"Study to Compare Adjuvant Immunotherapy of Bempegaldesleukin Combined With Nivolumab Versus Nivolumab After Complete Resection of Melanoma in Patients at High Risk for Recurrence","route":"/trials/nct04410445/"}]}}